BMJ (Clinical research ed.)

Use of Glucagon-like Peptide-1 Drugs Before Upper Stomach and Throat Exams and the Risk of Breathing Problems or Stopping the Procedure

Updated

Abstract

Among 43,365 adults with type 2 diabetes, the weighted risk of pulmonary aspiration was 4.15 per 1000 for GLP-1 receptor agonists and 4.26 for SGLT-2 inhibitors.

  • No increased risk of pulmonary aspiration was found for GLP-1 receptor agonist users compared to SGLT-2 inhibitor users (risk ratio 0.98).
  • GLP-1 receptor agonists were associated with a higher risk of endoscopy discontinuation (risk ratio 1.99) compared to SGLT-2 inhibitors.
  • The findings suggest that GLP-1 receptor agonists may lead to a higher risk of retained gastric content, influencing endoscopy procedures.
  • Results are based on a cohort study utilizing two US healthcare databases.

Simplified

Key numbers

4.15 per 1000 people
Risk of Pulmonary Aspiration
Weighted risk among users
9.79 per 1000 people
Risk of Endoscopy Discontinuation
Weighted risk among users
1.99
Discontinuation Risk Ratio
Pooled risk ratio for discontinuation of endoscopy

Full Text

We can’t show the full text here under this license.

Funding

Competing interests

Competing interests: All authors have completed the ICMJE uniform disclosure form at www.icmje.org/disclosure-of-interest/ and declare: SJC has a close family member employed by a Johnson & Johnson company and reports consultancy for Wolters-Kluwer and Alexion Pharmaceuticals. DJW reports consultancy for Novo Nordisk and serving as a data monitoring committee member for SOUL and FLOW trials. EP is principal investigator of a research grant to the Brigham and Women’s Hospital from Boehringer Ingelheim, not related to the topic of this work. CCT reports the following activities: Apollo Endosurgery – consultant/research support (consulting fees/institutional research grants); Bariendo – Founder/Board Member/Ownership Interest; BlueFlame Healthcare Venture Fund – Founder/General Partner; Boston Scientific – consultant (consulting fees)/research support (institutional research grant); Medtronic – consultant (consulting fees); ELLES – founder/board member/ownership interest; Endoquest Robotics – consultant, institutional research grant; Enterasense – founder, consultant, board member, ownership interest; EnVision Endoscopy – founder, board member, consultant, ownership interest; ERBE – institutional research grant; Fractyl – consultant/advisory board member (consulting fees)/research support; FujiFilm – consultant/institutional research grant; GI Dynamics – consultant (consulting fees)/ research support (institutional research grant); GI Windows – founder, board member, ownership interest; Lumendi – consultant/institutional research grant; Olympus/Spiration – consultant (consulting fees)/research support (Equipment Loans); Society for Metabolic and Bariatric Endoscopy (SMBE) – founder/president/ownership interest; Softac – consultant/ownership interest; USGI Medical – consultant (consulting fees)/advisory board member (consulting fees)/research support (institutional research grant); Xenter – consultant/SAB/ownership interest.
PubMed

What Lands in Your Inbox Each Week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free